<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617690</url>
  </required_header>
  <id_info>
    <org_study_id>mjj20221108</org_study_id>
    <nct_id>NCT05617690</nct_id>
  </id_info>
  <brief_title>Cyclopol on Electrophysiological Monitoring During Spine Surgery: a Randomized Controlled, Noninferiority Study</brief_title>
  <official_title>Effect of Cyclopol on Intraoperative Electrophysiological Monitoring in Spine Surgery: A Randomized Controlled, Noninferiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative visual function injury occurs after spinal cord, neurosurgery, ophthalmology&#xD;
      and other operations, which directly affects the postoperative quality of life of patients.&#xD;
      Flash visual evoked potential (FVEP) is important for evaluating visual function under&#xD;
      general anesthesia during operation. The changes of visual function can be observed and&#xD;
      recognized in time through the amplitude changes of FVEP, which can avoid or reduce the&#xD;
      visual function damage during operation. Anesthesia method determines the success and&#xD;
      variability of electrophysiological monitoring to a certain extent. The purpose of this study&#xD;
      is to investigate the effect of total intravenous anesthesia based on cyclopol on FVEP&#xD;
      compared with propofol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>N75-p100 amplitude of FVEP</measure>
    <time_frame>Intraoperative</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Visual Evoked Potentials</condition>
  <arm_group>
    <arm_group_label>Cyclopol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclopol</intervention_name>
    <description>Cyclopol 0.4mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. Anesthesia maintenance strategy is cyclopol 0.8-2.4 mg/kg/h and remifentanil 0.15 - 0.2 μg/kg/h</description>
    <arm_group_label>Cyclopol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol 1-3mg/kg, sufentanil 0.2-0.4ug/kg and rocuronium 0.6mg/kg will be used for anesthesia induction. The anesthesia maintenance strategy is propofol 4-8mg/kg/h and remifentanil 0.15 - 0.2 μ g/kg/h</description>
    <arm_group_label>Propofol group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients undergoing elective spinal surgery under general anesthesia;&#xD;
&#xD;
          2. Intraoperative electrophysiological monitoring is required;&#xD;
&#xD;
          3. 18-65 years old;&#xD;
&#xD;
          4. ASA I-III;&#xD;
&#xD;
          5. Sign the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with visual impairment;&#xD;
&#xD;
          2. Patients with severe liver or kidney disease;&#xD;
&#xD;
          3. Uncontrolled hypertension, diabetes, severe arrhythmia or unstable angina pectoris;&#xD;
&#xD;
          4. Have mental illness or unable to communicate;&#xD;
&#xD;
          5. BMI≥30kg/㎡;&#xD;
&#xD;
          6. Abuse of analgesics and drug abuse history;&#xD;
&#xD;
          7. Muscle weakness, motor dysfunction or neuromuscular junction disease before operation;&#xD;
&#xD;
          8. Preoperative somatosensory dysfunction;&#xD;
&#xD;
          9. Retain trachea catheter after operation;&#xD;
&#xD;
         10. Narcotic drugs and silicone allergy;&#xD;
&#xD;
         11. Visual evoked potential monitoring was rejected.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruquan Han</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiajia Ma</last_name>
    <phone>861059976658</phone>
    <email>majj04@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100070</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Ruquan Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

